ArticleMaterials today. Bio2025
Shield microneedles loaded with biphasic-delivery liposomes modulate skin oxidation/immunity dual-axis for psoriasis therapy.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Can Microneedle-Nanocarrier Platforms Deliver True Tolerogenic Immunotherapy for Psoriasis?Vaccines · 2026Review
- Ginsenosides: potential therapeutic implications in neurodegenerative diseases by inhibiting ferroptosis.Molecular biology reports · 2026Review
- Microfluidic Nanocomposite Lubricating Microgels Localized Deliver Celastrol for Remodeling the Immune Microenvironment to Enhance Osteoarthritis Treatment.Research (Washington, D.C.) · 2026Article
- Microneedle-Based Technologies for Long-Acting Transdermal Drug Delivery in Wearable Devices.Sensors (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
5-Aminolevulinic acid-based photodynamic therapy (ALA-PDT) has emerged as a promising therapeutic strategy for psoriasis owing to its non-invasiveness and high selectivity. However, clinical translation is hindered by inadequate cutaneous permeability and the paradoxical interplay between pro-apoptotic effect and oxidative stress. Therefore, this study develops biphasic delivery liposome loaded with 5-ALA and ginsenoside Rg3, and designs hydrogel-backed shield microneedles (SMNs) inspired by shield tunneling principles to achieve efficient delivery. Flow cytometry analysis demonstrates that the biphasic delivery liposome harnesses Rg3 to activate the SOD/CAT antioxidant enzyme system, thereby scavenging excess reactive oxygen species (ROS) generated by 5-ALA-PDT. Incorporation of this liposome into shield microneedles disrupts the psoriatic-thickened stratum corneum barrier and enhances its cutaneous permeation. In an imiquimod-induced mouse model of psoriasis, the microneedle system ameliorates skin lesions and restores immune homeostasis by inhibiting STAT3 phosphorylation, modulating splenic Th17 cell differentiation, and down-regulating serum IL-17A levels. Importantly, this regulatory effect on key inflammatory cytokines, including IL-6 and TNF-α, is further validated using an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.